Literature DB >> 23867014

Assessment of viral replication in eggs and HA protein yield of pre-pandemic H5N1 candidate vaccine viruses.

Xianghong Jing1, Jackeline Soto, Yamei Gao, Kathryn Phy, Zhiping Ye.   

Abstract

H5N1 infection and the potential for spread from human to human continue to pose a severe public health concern. Since vaccination remains the most effective way to prevent a potential H5N1 pandemic, the World Health Organization (WHO) Collaborating Centers (CCs) and Essential Regulatory Laboratories (ERLs) engineered and developed a panel of H5N1 pre-pandemic vaccine viruses for pandemic vaccine preparedness as well as production of antigen potency testing reagents (reference antigen and reference anti-serum) for vaccine standardization. To develop a strategy utilizing a number of biochemical methods for the characterization of the viral growth properties and protein yield in eggs, we have selected eight H5N1 pre-pandemic viruses and determined the viral Egg Infectious Dose 50 (EID50), total protein yield, hemagglutinin (HA) to nucleoprotein (NP) ratios (HA:NP), and HA1 content of each virus. Our results showed that all the tested H5N1 vaccine viruses grew to high titers in eggs. The total viral protein yield varies within a narrow range, whereas there were greater differences in the HA:NP protein ratios among the eight viruses. The RP-HPLC based HA1 content analysis demonstrated that the viruses A/Anhui/1/2010, A/Hubei/1/2005, and A/goose/Guiyang/337/2006 contained higher HA contents than other five viruses including A/Vietnam/1203/2003. Our approach for analyzing virus growth and protein yield will allow us identify optimal vaccine virus in a timely manner. In addition, we successfully purified the HA proteins of H5N1 vaccine viruses by optimizing bromelain cleavage conditions. Our studies on the HA protein purification may improve the quality control of the production of influenza vaccine test reagent. Published by Elsevier Ltd.

Entities:  

Keywords:  HA bromelain cleavage; HA purification; Influenza H5N1 virus protein yield; Influenza pandemic preparedness

Mesh:

Substances:

Year:  2013        PMID: 23867014     DOI: 10.1016/j.vaccine.2013.07.011

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

1.  Development of American-Lineage Influenza H5N2 Reassortant Vaccine Viruses for Pandemic Preparedness.

Authors:  Po-Ling Chen; Alan Yung-Chih Hu; Chun-Yang Lin; Tsai-Chuan Weng; Chia-Chun Lai; Yu-Fen Tseng; Ming-Chu Cheng; Min-Yuan Chia; Wen-Chin Lin; Chia-Tsui Yeh; Ih-Jen Su; Min-Shi Lee
Journal:  Viruses       Date:  2019-06-11       Impact factor: 5.048

2.  Highly pathogenic avian influenza A/Guangdong/17SF003/2016 is immunogenic and induces cross-protection against antigenically divergent H7N9 viruses.

Authors:  Peter Radvak; Martina Kosikova; Yuan-Chia Kuo; Xing Li; Richard Garner; Falko Schmeisser; Ivan Kosik; Zhiping Ye; Jerry P Weir; Jonathan W Yewdell; Hang Xie
Journal:  NPJ Vaccines       Date:  2021-02-26       Impact factor: 7.344

3.  A novel approach for preparation of the antisera reagent for potency determination of inactivated H7N9 influenza vaccines.

Authors:  Falko Schmeisser; Xianghong Jing; Manju Joshi; Anupama Vasudevan; Jackeline Soto; Xing Li; Anil Choudhary; Noel Baichoo; Josephine Resnick; Zhiping Ye; William McCormick; Jerry P Weir
Journal:  Influenza Other Respir Viruses       Date:  2016-01-29       Impact factor: 4.380

4.  Development and characterization of standard reagents for cell-based prepandemic influenza vaccine products.

Authors:  Chia-Chun Lai; Tsai-Chuan Weng; Po-Ling Chen; Yu-Fen Tseng; Chun-Yang Lin; Min-Yuan Chia; Wang-Chou Sung; Min-Shi Lee; Alan Yung-Chih Hu
Journal:  Hum Vaccin Immunother       Date:  2020-03-02       Impact factor: 3.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.